Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dengue is a mosquito-borne viral disease that is endemic in India. We evaluated the immunogenicity and safety of recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in Indian adults. In this observer-blind, randomized, placebo-controlled, Phase II study, adults aged 18-45 years were randomized 2:1 to receive CYD-TDV or placebo at 0, 6 and 12 months in sub-cutaneous administration. Immunogenicity was assessed using a 50% plaque reduction neutralization test (PRNT50) at baseline and 28 days after each study injection. 189 participants were enrolled (CYD-TDV [n = 128]; placebo, [n = 61]). At baseline, seropositivity rates for dengue serotypes 1, 2, 3 and 4 ranged from 77.0% to 86.9%. Seropositivity rates for each serotype increased after each CYD-TDV injection with a more pronounced increase after the first injection. In the CYD-TDV group, geometric mean titres (GMTs) were 2.38 to 6.11-fold higher after the third injection compared with baseline but remained similar to baseline in the placebo group. In the CYD-TDV group, the GMTs were 1.66 to 4.95-fold higher and 9.23 to 24.6-fold higher after the third injection compared with baseline in those who were dengue seropositive and dengue seronegative, respectively. Pain was the most commonly reported solicited injection site reaction after the first injection in both the CYD-TDV (6.3%) and placebo groups (4.9%), but occurred less frequently after subsequent injections. No serious adverse events were vaccine-related, no immediate unsolicited adverse events, and no virologically-confirmed cases of dengue, were reported during the study. The immunogenicity and safety of CYD-TDV was satisfactory in both dengue seropositive and seronegative Indian adults.
a Maulana Azad Medical College & Hospital ; New Delhi , India.
Anand Prakash
AP
Dubey
b Dr DY Patil Medical College & Hospital ; Pimpri, Pune , India.
Sharad
S
Agarkhedkar
c Christian Medical College & Hospital ; Ludhiana , India.
Jugesh
J
Chhatwal
d Sr Professor of Medicine; MS Ramaiah Medical College & Hospitals ; Bangalore , India.
Arun
A
Narayan
e Medical College ; Kolkata , India.
Satyabrata
S
Ganguly
f Clinical Research & Development ; Sanofi Pasteur , Singapore.
T Anh
TA
Wartel
f Clinical Research & Development ; Sanofi Pasteur , Singapore.
Alain
A
Bouckenooghe
f Clinical Research & Development ; Sanofi Pasteur , Singapore.
Josemund
J
Menezes
D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D003715:Dengue / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000009:adverse effects / Q000276:immunology*; D003716:Dengue Virus / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007194:India; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D010919:Placebos; D000069078:Seroconversion; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology; D055815:Young Adult
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053059:Dengue Vaccines; D010919:Placebos; D014613:Vaccines, Attenuated
CYD vaccine; India; dengue; immunogenicity; live attenuated vaccine; phase II trial; recombinant; safety; tetravalent dengue vaccine